Skip to main content

PERSPECTIVE article

Front. Psychiatry
Sec. Psychopharmacology
Volume 15 - 2024 | doi: 10.3389/fpsyt.2024.1427482

Clinical challenges in the dosing and titration of cariprazine

Provisionally accepted
Cedo Miljevic Cedo Miljevic *Petar Vukovic Petar Vukovic Ana Munjiza-Jovanovic Ana Munjiza-Jovanovic
  • Institute of Mental Health (Belgrade), Belgrade, Serbia

The final, formatted version of the article will be published soon.

    The introduction of a new psychopharmaceutical medication instead of the previous one always poses a certain challenge. In the case of antipsychotics (AP), these problems are considerably more complicated and are mainly caused by the question of dose equivalents, but also by the pharmacokinetic properties of the drug. In the case of partial dopamine D2 agonists, an additional issue is the possibility of deterioration when switching from the previous D2 antagonists to these drugs. Cross-titration is therefore generally recommended. Finally, due to the capsule form, it is not possible to increase the dose of cariprazine by less than 1.5 mg during titration. In this paper, we have presented our proposal to replace the most commonly used second-generation APs with the third-generation AP cariprazine. We have taken into account the dose equivalents, the pharmacological forms of the drugs and their pharmacokinetic and pharmacodynamic properties.

    Keywords: Cariprazine, Antipsychotics, Psychopharmacology, Cross-titration, partial D3 agonist Article type: Perspective

    Received: 03 May 2024; Accepted: 08 Aug 2024.

    Copyright: © 2024 Miljevic, Vukovic and Munjiza-Jovanovic. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Cedo Miljevic, Institute of Mental Health (Belgrade), Belgrade, Serbia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.